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Background: Our objective was to evaluate the effect of background biological disease-modifying anti-rheumatic
drugs (bDMARDs) and/or corticosteroids (CS) on response to nonsteroidal anti-inflammatory drugs (NSAIDs) in
rheumatoid arthritis (RA) patients.
Methods: The following efficacy endpoints were evaluated using time-weighted change from baseline in a 12-week,
randomized controlled clinical trial with etoricoxib: Patient Global Assessment of Pain, Swollen Joint Count, Tender Joint
Count, Health Assessment Questionnaire. The following three treatment groups were evaluated: placebo, pooled
etoricoxib 10/30/60 mg, and etoricoxib 90 mg. Screening values, values post flare, as well as changes after treatment
were analyzed.
Results: Of the 1014 patients screened, 761 were randomized; 50% were on no background bDMARDs and/or CS
therapy, 23% used bDMARDs, 34% used CS, and 8% used both bDMARDs and CS. It was demonstrated that RA patients
on bDMARDs or CS had similar pain levels at screening as patients without this co-medication. They experienced flare
upon NSAID withdrawal and demonstrated dose-dependent pain improvement with etoricoxib.
Conclusion: These results support that RA patients receiving bDMARDs or CS may still require the use of concomitant
analgesics to treat pain. Clinicians should continue to monitor and treat pain even after initiating a bDMARD and/or CS.
Trial Registration: [clinicaltrials.gov; NCT00264147]
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A majority of patients with rheumatoid arthritis (RA)
list pain as a priority for improvement [1,2]. Advances
in therapeutics (i.e., corticosteroids [CS], synthetic
disease-modifying antirheumatic drugs (sDMARDs),
and biological DMARDs (bDMARDs) have demonstrated
efficacy in reducing inflammation and controlling joint* Correspondence: t.k.kvien@medisin.uio.no
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unless otherwise stated.damage in patients with RA [3-5]. However, a building
consensus in pain research suggests that chronic persist-
ent pain may result in both peripheral and central nervous
system plasticity, establishing a parallel disease process,
and that chronic pain, regardless of etiology, should itself
be considered a disease [6]. Moreover, recent research has
suggested that RA patients can continue to experience sig-
nificant levels of pain even when underlying disease
markers of RA (i.e. DAS-28) are controlled by modern
therapeutic regimens [6,7].his is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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any additive role in RA beyond the use of bDMARDs and
CS, it would be predicted that three relationships should
hold true: (1) patients with RA and on bDMARDs and/or
CS who stop their NSAIDs should have the same degree
of flare in RA symptoms as those who are not on such co-
medication; ( 2) those on bDMARDs and/or CS should
experience the same degree of response with the addition
of another NSAID; and (3) dose–response relationships
should be similar in patients on versus not on bDMARDs
and/or CS. The current report addresses these relation-
ships in post-hoc analyses from a primary dose-range-
finding clinical trial with etoricoxib, a COX-2 selective
NSAID, in RA patients.
Methods
Study design and patients
These post-hoc analyses are based on a randomized,
placebo-controlled, double-blind, multicenter, parallel-
group, 5-arm, 12-week trial of etoricoxib (Sponsor
protocol # 086, Clinical Trials Registry # NCT00264147)
[8]. The study was conducted at 90 sites in four countries
(United States, Canada, Colombia, and Switzerland) fol-
lowing approval by local Independent Ethics Committees
or Investigational Review Boards, and it was conducted in
accordance with Good Clinical Practice principles. The
following Institutional Review Boards and Independent
Ethics Committees approved the study: College of Physicians
and Surgeons of Alberta Research Ethics Review Committee;
Ottawa Hospital Research Ethics Board; Institutional Review
Board (IRB) of Institutional Review Board Services;
Biomedical Research Ethics Board University of Manitoba;
Western Institutional Review Board; University of Louisville
Human Subjects Protection Program Office; Gundersen
Lutheran Ltd. Human Subjects; University of North Texas
Health Science Center at Forth Worth Committee;
Kantonale Ethikkommission des Kantons Graubünden;
Comité de Etica de la Fundación Instituto de Reumatologia
Fernando Chalem. Before enrollment, all patients provided
written informed consent. Eligible patients were ≥18 years
of age and had a clinical diagnosis of RA according to the
ARA 1987 revised criteria ≥6 months before enrollment
[8]. Patients who flared following withdrawal of stable pre-
study NSAIDs were randomized in a 1:1:1:1:1 ratio to pla-
cebo, or one of four doses of etoricoxib: 10 mg, 30 mg,
60 mg, or 90 mg daily.
Endpoints and analyses according to use of bDMARDs
and CS
In order to ensure that the findings were generalizable
across endpoints, four responsive study endpoints were
used that included physician and patient measures:
100 mm pain visual analogue scale (VAS, range 0–100,
100 = worst pain); swollen joint count (out of 66 joints,66-SJC); tender joint count (out of 68 Joints, 68-TJC);
and health assessment questionnaire (HAQ) score (range
0–3, 3 = worst health).
Three subpopulations were evaluated based on the
dose–response relationships established in the primary
trial analysis: patients on the labeled dose of etoricoxib
in RA (90 mg), those on other doses of etoricoxib (10-,
30-, and 60-mg groups combined for these analyses),
and patients on placebo. Each of these three groups was
further considered based on four possible combinations
of bDMARDs and/or CS use (no bDMARD or CS,
bDMARD alone, CS alone, or both bDMARD and CS).
Those on DMARDs and CS before study entry were
continued on the same doses throughout the trial.
Statistical analysis
The primary population for efficacy analyses was all ran-
domized patients who received ≥1 dose of study medica-
tion and had valid baseline and ≥1 on-treatment
measurement. Summary statistics for efficacy endpoints
were reported by treatment and concomitant medication
usage status. Least square means with 95% confidence
intervals (CIs) of time-weighted changes from baseline
over 12 weeks were generated from an ANCOVA model
with terms for baseline parameter, treatment, concomitant
medication status, and its interaction with treatment. Due
to the limited number of patients in certain strata, the re-
sults are mainly for descriptive purposes and should be
interpreted accordingly. Our study hypothesis was that
etoricoxib would provide similar benefit across the four
study endpoints evaluated, independent of the use of bio-
logical or corticosteroid co-medication. However, these




Baseline demographics were reported in the primary
publication for this study [8]. The bDMARDs used in
this study included the following: etanercept (n = 68),
adalimumab (n = 64), and infliximab (n = 41). Although
bDMARDs or CS therapy was used in 23% and 34% of
patients, respectively, the subgroup of patients on both
agents was small (8%).
Concomitant sDMARDs included methotrexate, sulfa-
salazine, hydroxycholoquine, gold salts, and leflunomide.
Forty percent of patients were taking sDMARDs without
bDMARDs or CS, while 19% were not taking sDMARDs,
bDMARDs, or CS.
Screening and baseline values
Screening values (i.e., before randomization and with-
drawal of NSAIDs) of the four endpoints were similar
across the four subgroups (Table 1). A large pain flare
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background RA treatment with bDMARD and/or CS.
Increases in tender and swollen joint counts and HAQ-
scores were also observed across all four subgroups.
Response to etoricoxib
Improvements in pain VAS were of similar magnitude
across the four subgroups, independent of concomitant
treatment with bDMARDs and/or CS (Figure 1). In addition,
the data indicated a dose–response relationship from pla-
cebo, to the pooled 10-/30-/60-mg dose group, and to the
etoricoxib 90-mg dose (Figure 1). However, this dose–re-
sponse relationship was not evident in the small group
(n = 16) using both bDMARDs and CS. Overall, results
for the other endpoints (66-SJC, 68-TJC, and HAQ-score)
were similar to those observed for pain VAS (Figure 1),
suggesting that the improvement was consistent across
measures performed by patients and physicians.
Discussion
No prior studies have examined whether patients with
residual pain on bDMARDs benefit from treatment withTable 1 Screening means and baseline means (post flare) for























bDMARDs = Biological disease-modifying antirheumatic drugs;CS = Corticosteroids;V
66-SJC = Swollen joint count of 66 joints; 68-TJC = Tender joint count of 68 joints; H
*p = 0.050 for difference between baseline values for placebo and etoricoxib 10/30/
etoricoxib (Other than these two instances out of the 96 treatment comparisons th
in screening/baseline values).NSAIDs; these analyses suggest that NSAID treatment
in these patients may benefit the patient. Although re-
mission through DMARD use is the focus of treatment
in RA [5], pain is still an important issue for patients
[1,2]. Thus, from a patient perspective, these data are
important for the clinical management of patients with
RA, in particular patients with established disease.
Previous studies demonstrate that pain medication
usage has persisted even after the introduction of
bDMARDs. A study of 24,000 Medicaid patients from
1995 to 2004 showed that, despite increased bDMARDs
use, additional pain medication also increased during
this time period [9]. Another analysis of healthcare costs
in patients on bDMARDs showed high levels of use
NSAID and opioid use to control persistent pain [10].
The data reported in these analyses support a role of
NSAIDs and selective COX-2 inhibitor therapy, in this
case, etoricoxib, as part of a multimodal treatment strat-
egy, alongside treatments that control inflammation in
patients who continue to suffer from pain. To the histor-
ical views that pain in RA is largely related to joint in-
flammation or joint damage [11], these data suggest thatpain, swollen and tender joint counts and HAQ scores by
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Figure 1 Least square means (95% CI) change from baseline in efficacy endpoints by trial treatments and concomitant therapy. A) pain
(0–100 mm VAS); B) swollen joint count (number of joints); C) tender joint count (number of joints); D) health assessment questionnaire (points).
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the peripheral and central nervous system that contrib-
ute to persistent chronic pain beyond the joint pathology
[6,7,12]. Importantly, prostaglandins have effects along
the entire nociceptive pathway, including the spinal
cord, where COX-1 and COX-2 enzymes are expressed
[13,14]. The ability of an NSAID to have a central effect
through penetration of the blood–brain barrier is vari-
able and depends on various molecular characteristics
such as size, lipid solubility, and capacity to bind to
plasma proteins [15]. Etoricoxib has demonstrated to be
highly bound to plasma proteins [16], and central ner-
vous system penetration has been shown in a study in
hip surgery where oral etoricoxib dosing led to meaningful
concentrations in cerebrospinal fluid [17]. Thus, NSAIDs
such as etoricoxib may have analgesic effects beyond the
level of the joint, thereby targeting nervous system plastic
responses both in the periphery and, depending on the
agent, in the central nervous system as well.
These analyses have limitations related to the nature of
post-hoc analyses, and additional trials will be needed toconfirm these data. The small number of patients in the sub-
groups limited appropriate sample size calculations and
comparative statistical analyses across treatment groups. Par-
ticularly, the number of patients in the combined sDMARD
and CS group was extremely small. We are not able to make
any statements about interactions between sDMARDs and
NSAIDs, but most of the patients in all groups were on
sDMARDs. Additional limitations are related to the patient
population. Average disease duration was 10 years; thus, our
results seem to be most relevant for patients with established
RA. Additionally, the percentage of patients not on any kind
of DMARD or CS was 19%, which may reflect the time
period (early 2006) and the multinational nature of this trial
[18]. Also, patients may have had high disease activity and
were selected after exhibiting a flare of symptoms
upon withdrawal of previous NSAID therapy, indicat-
ing a proclivity to respond to therapy with etoricoxib
while on background therapy. Nonetheless, these data
indicate that there is a population of patients with
RA who will not obtain adequate pain management
with bDMARDs or CS alone.
Kvien et al. BMC Musculoskeletal Disorders  (2015) 16:26 Page 5 of 5Conclusions
Despite these limitations, the consistent trends observed
across the four endpoints support that etoricoxib, as an
example of an NSAID, provides symptomatic efficacy in
RA patients in the presence of concomitant treatment
with bDMARDs and/or CS. Given the similarity in the
magnitude of flare across the subgroups, the magnitude
of response to introduction of etoricoxib and the dose
response across the subgroups, these data suggest that
NSAIDs, and etoricoxib in particular, have a role in a
multimodal treatment strategy to control RA signs and
symptoms. However, prescriptions should follow a
benefit-risk consideration according to current treatment
recommendations.
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